To date, Hikma has supplied 21 generic injectable medicines to hospitals in France through a third-party. Following the approval of Hikma France and the opening of a new commercial office outside Paris, it will now supply medicines to hospitals directly. This broadened portfolio will span several therapeutic areas including anti-infective, cardiovascular and central nervous system.

Hikma has an established and growing presence in Europe with high-quality manufacturing plants in Portugal, Italy and Germany, supplying injectable products to North America, the Middle East and North Africa and Europe.

Riad Mishlawi, President of Hikma Injectables commented:

“The expansion into France is an important step forward in our European growth ambition. Hikma France will complement our existing presence in Europe. I am excited by the opportunity to supply French hospitals and their patients with high-quality and affordable injectable medicines. We look forward to building our presence here as we aim to become a key player in the French hospital market.”